Menu

Corning Life Sciences to Feature 3D Cell Culture Technologies at SLAS 2019

Feb 13, 2019
The Scientist Staff

Corning Incorporated (NYSE: GLW) will showcase advanced 3D cell culture technologies and workflow solutions for spheroids, organoids, tissue models, and applications including ADME/toxicology at the Society for Laboratory Automation and Screening (SLAS) conference, Feb. 2-6 in Washington, D.C. The company will highlight expanded product offerings and other 3D applications in oncology, neuroscience, toxicity screening, and more. Corning experts will be able to speak to these applications, the impact of 3D in research and development and drug discovery, as well as perspectives in disease modeling and high-throughput screening. Discussion topics will include how the use of physiologically relevant 3D cell cultures is facilitating discovery and validation of novel drug targets and accelerating clinical translation of drug candidate screening for safety and efficacy. Spokespeople will be available for tours and to share insights at booth #413. Corning and its customers will also offer several presentations and posters during SLAS including: Presentations and Tutorials • Sunday, February 3, 2019 Short Course: Set-up and Validation of 3D Primary, Stem Cell and Immortalized Cultures for Downstream Microplate Reader and Imaging Applications Presented by: Brad Larson, BioTek Instruments, Inc., Mark E. Rothenberg Ph.D., Corning Life Sciences 8:00 a.m. – 12:00 p.m. Convention Center, room 143C • Monday, February 4, 2019 Tutorial: Spheroids and Mini Brains for Studying Glioblastoma Presented by: Amanda Linkous, Ph.D., NCI Center for Systems Biology of Small Cell Lung Cancer at Vanderbilt, Hilary Sherman, Corning Life Sciences 2:00 – 2:45 p.m. Convention Center, Room 151A • Tuesday, February 5, 2019 Podium Presentation: Fully Automated Large Scale uHTS using 3D Cancer Organoid Models for Phenotypic Drug Discovery Applications Presented by: Virneliz Fernandez Vega, Scripps Research Institute 12:00 – 12:30 p.m. • Wednesday, February 6, 2019 Podium Presentation: High-throughput, CRISPR Based 3D Screening Platform for Rapid Discovery of Novel CDK4/6 Inhibitor Resistance Presented by: Taraka Sai Pavan Grandhi, Ph.D, Genomics Institute of Novartis Research Foundation 11:00 AM - 11:30 AM Posters Corning Life Sciences and its customers will be presenting several posters throughout the meeting including those focused on high-throughput screening, 3D assay development, air-liquid interface models and other 3D application areas. If you are interested in scheduling a booth tour and meeting with a member of the Corning team to learn more about how Corning is transforming and enabling the future of 3D with innovative technologies and workflow solutions, please contact: Leanne Stone 520-490-0719 lstone@spectrumscience.com

March 2019

Going Under

Dissecting the effects of anesthetics

Marketplace

Sponsored Product Updates

The Complex Biology of Macrophages: Origins, Functions, and Activation States
The Complex Biology of Macrophages: Origins, Functions, and Activation States
Download this poster from R&D Systems for a detailed overview of macrophage markers, functions, development, specialization, and activation!
A Guide to Measuring Drug-Target Residence Times with Biochemical Assays
A Guide to Measuring Drug-Target Residence Times with Biochemical Assays
Download this guide from BellBrook Labs to learn about how to use Transcreener® biochemical assays to measure drug-target residence times, complete with examples and case studies!
Beckman Coulter Life Sciences To Launch New Product Via Live Stream Event
Beckman Coulter Life Sciences To Launch New Product Via Live Stream Event
After visiting labs around the world to identify ways to advance its industry-leading cell counting technology, Beckman Coulter Life Sciences will host a live streaming event on March 26 at 10 a.m. EDT / 7 a.m. PDT to announce its latest product innovation.  
Cybrexa Therapeutics to Present First Data and Unveil Details for its alphalex™-PARP Inhibitor Lead Candidate CBX-11 at AACR Annual Meeting 2019
Cybrexa Therapeutics to Present First Data and Unveil Details for its alphalex™-PARP Inhibitor Lead Candidate CBX-11 at AACR Annual Meeting 2019
Cybrexa Therapeutics, a biotechnology company developing a new class of cancer therapeutics through its alphalex™ tumor targeting platform, today announced that Vishwas Paralkar, PhD, Chief Scientific Officer of Cybrexa, will present the first set of preclinical data supporting its alphalex™-PARP inhibitor lead candidate, CBX-11, at the American Association for Cancer Research (AACR) Annual Meeting 2019, being held March 29 – April 3 in Atlanta, Georgia. At the meeting, the Company will unveil the FDA-approved poly ADP-ribose polymerase (PARP) inhibitor conjugated in CBX-11.